Current Report Filing (8-k)
June 01 2020 - 2:55PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of
1934
|
Date of
Report (Date of earliest event reported):
|
|
May 26, 2020
|
PREMIER BIOMEDICAL, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
(State
or other
jurisdiction
of incorporation)
|
|
000-54563
(Commission
File
Number)
|
|
27-2635666
(I.R.S.
Employer
Identification
No.)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
P.O. Box 25
Jackson Center, PA 16133
(Address
of principal executive offices) (zip code)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(814) 786-8849
(Registrant’s
telephone number, including area code)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Former
name or former address, if changed since last report.)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[_]
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[_]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[_]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[_]
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth
company
[_]
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
[_]
Section 5 – Corporate Governance and Management
Item 5.02
Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On May 26, 2020, the following officers and directors
resigned:
|
William
A. Hartman
|
|
President,
Chief Executive Officer, and acting Chairman
|
|
|
|
|
|
Dr.
Mitchell S. Felder
|
|
Chairman
of the Scientific Advisory Board
|
|
|
|
|
|
Heidi
H. Carl
|
|
Chief Financial Officer, Secretary, Treasurer and
Director
|
|
|
|
|
|
Dr.
Patricio F. Reyes
|
|
Chief Technology Officer and Director
|
|
|
|
|
|
John S.
Borza
|
|
Vice President and Director
|
|
|
|
|
|
Jay
Rosen
|
|
Director
|
|
|
|
|
|
John
Pauly
|
|
Director
|
There
is no disagreement between the resigning officers and directors and
Premier on any matter relating to Premier’s operations,
policies or practices.
Also on May 26, 2020, David Caplan, the sole remaining member of
our Board of Directors, was appointed as our President, Secretary,
and Treasurer.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
Premier Biomedical, Inc.
|
|
|
|
|
|
|
|
Dated:
June 1, 2020
|
/s/
David Caplan
|
|
|
By:
David Caplan
|
|
|
Its:
President
|
Premier Biomedical (PK) (USOTC:BIEI)
Historical Stock Chart
From Oct 2024 to Nov 2024
Premier Biomedical (PK) (USOTC:BIEI)
Historical Stock Chart
From Nov 2023 to Nov 2024
Real-Time news about Premier Biomedical Inc (PK) (OTCMarkets): 0 recent articles
More Premier Biomedical Inc News Articles